Who With Gastric Intestinal Metaplasia Requires Endoscopic Surveillance?

Answer in brief: Routine surveillance is not necessary for every patient with gastric intestinal metaplasia (GIM). Surveillance is most defensible when GIM is extensive or incomplete, when there is a strong family history or other gastric-cancer risk, or when the baseline examination did not adequately stage the stomach. High-quality endoscopy, systematic biopsies and eradication of H. pylori are central to risk reduction.

Risk stratification matters more than the mere presence of GIM

GIM is a marker of the gastric precancerous cascade, but its absolute cancer risk varies substantially. The 2025 ACG gastric premalignant conditions guideline emphasizes extent, histologic subtype and patient-level risk factors rather than treating all GIM as equivalent. Limited antral GIM is lower risk than corpus-extending disease; incomplete-type GIM is more concerning than complete-type GIM.

The first clinical task is therefore not simply to document “GIM present,” but to decide whether the index examination actually established the distribution and severity of disease.

Who is higher risk?

Features that should raise concern include extensive/corpus-involving GIM, incomplete histology, severe atrophy or metaplasia, a first-degree family history of gastric cancer, origin from or long-term residence in a high-incidence region, and persistent H. pylori infection. Autoimmune gastritis and hereditary cancer syndromes also modify risk.

What should the endoscopist do?

A surveillance examination should be a high-quality diagnostic examination rather than a quick repeat EGD. Carefully inspect the entire stomach, use high-definition imaging with image enhancement when available, target visible abnormalities, and obtain mapping biopsies from appropriate gastric regions. The pathology report should allow the clinician to distinguish limited from extensive disease.

How often should surveillance occur?

For higher-risk GIM, the 2025 ACG framework commonly uses a three-year interval, with shorter intervals considered when multiple risk factors coexist or when dysplasia/visible lesions change the risk category. For low-risk, well-staged non-dysplastic GIM, no ongoing surveillance may be reasonable. When the original examination did not include adequate mapping, a repeat examination can be used to establish risk before committing the patient to long-term surveillance.

Do not forget H. pylori

Every patient with gastric premalignant change should be evaluated for H. pylori and treated if infected, with confirmation of eradication. Eradication does not eliminate all subsequent cancer risk once advanced mucosal change is present, but it removes a major carcinogenic driver.

What trainees should remember

GIM is not a binary surveillance diagnosis. Stage the stomach, define extent and subtype, identify patient-level cancer risk, eradicate H. pylori, and reserve repeated endoscopy for patients whose risk justifies it.

Frequently asked questions

Does every patient with GIM need an EGD every three years?

No. Three-year surveillance is mainly a risk-based strategy for higher-risk patients; low-risk, adequately staged GIM may not require continued surveillance.

Should visible lesions be managed as routine GIM?

No. A visible lesion or dysplasia changes management and generally requires expert endoscopic assessment and targeted therapy or more intensive surveillance.

References and further reading

1. Thomson ABR. Best Practice Guidelines in Gastroenterology Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Endoscopy and Diagnostic Imaging, Parts I-II. CAPstone Academic Publishers; 2012.

3. Morgan DR, et al. ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. Am J Gastroenterol. 2025.

4. Chey WD, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024.